DUBLIN, June 10, 2016 /PRNewswire/-- Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced that new data presented at the American Headache Society (AHS) annual scientific meeting reveals differences between the way men and women react to migraines, suggesting underlying disparities in headache characteristics and progression.i The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study longitudinally explored the causes and burden of Chronic Migraine and Episodic Migraine, both part of the spectrum of migraine disorders but distinct clinical entities. Chronic Migraine is a neurological condition characterized by 15 or more headache days per month, with headaches lasting four hours a day or longer, and at least eight of those headache days being associated with migraine, while Episodic Migraine is defined as less than 15 headache days per month.ii
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
Migraine is one of the most common neurologic disorders in both men and women, but its misperception as a "women's disease" may contribute to migraine stigma in men.i The web-based-study of 16,789 men and women with migraine assessed differences in sociodemographics, headache symptomology, disability, diagnosis, and treatment.i
"Despite gender differences in attack features, these conditions are disabling in men. Chronic Migraine, in particular, has been found to impact daily life inside and outside the home," explained Dr. Richard B. Lipton, an Edwin S. Lowe Professor and Vice Chair of Neurology, Professor of Epidemiology and Population Health and Professor of Psychiatry and Behavioral Sciences at the Albert Einstein College of Medicine.iii "Men need to know that there are treatments available and it's okay to ask for help."
Data indicated differences in the way men and women receive diagnoses, interact with healthcare providers and manage the conditions.
According to Dr. Lipton, "As we work to better understand whether men have a different migraine pathophysiology than women, it's important to encourage everyone – men and women – who is experiencing symptoms to seek an accurate diagnosis."
Funding for the Chronic Migraine Epidemiology and Outcomes (CaMEO) study was provided by Allergan plc.
"Allergan is dedicated to advancing research to help the estimated 36 million Americans who are living with the debilitating effects of migraine,[iv]" said David Nicholson, Chief R&D Officer at Allergan. "The more information patients have, the better equipped they will be to make critical decisions about their own health, including when to seek help and what treatment options are available."
For more information about Chronic Migraine, including a screening tool, visit MyChronicMigraine.com.
About AllerganAllergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.
For more information, visit Allergan's website at www.allergan.com.
Forward-Looking StatementStatements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 (certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
For more information, visit Allergan's website at www.allergan.com.
iScher I. Ann, PhD, et al. Epidemiology of Migraine in Men: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.iiHeadache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 3rd edition. Cephalalgia. 2013;33(9):629–808.iiiKatsarava, Zaza, et al. "Defining the Differences Between Episodic Migraine and Chronic Migraine." Current Pain and Headache Reports. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3258393/ (Nov. 15, 2011).ivAmerican Migraine Foundation. "About Migraine." http://www.americanmigrainefoundation.org/about-migraine/ (May 16, 2016)
CONTACTS:
Media: Mark Marmur(973) 906-1526
Lisa Kim(714) 246-3843
Advertisement
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
Migraine is one of the most common neurologic disorders in both men and women, but its misperception as a "women's disease" may contribute to migraine stigma in men.i The web-based-study of 16,789 men and women with migraine assessed differences in sociodemographics, headache symptomology, disability, diagnosis, and treatment.i
Advertisement
"Despite gender differences in attack features, these conditions are disabling in men. Chronic Migraine, in particular, has been found to impact daily life inside and outside the home," explained Dr. Richard B. Lipton, an Edwin S. Lowe Professor and Vice Chair of Neurology, Professor of Epidemiology and Population Health and Professor of Psychiatry and Behavioral Sciences at the Albert Einstein College of Medicine.iii "Men need to know that there are treatments available and it's okay to ask for help."
Data indicated differences in the way men and women receive diagnoses, interact with healthcare providers and manage the conditions.
According to Dr. Lipton, "As we work to better understand whether men have a different migraine pathophysiology than women, it's important to encourage everyone – men and women – who is experiencing symptoms to seek an accurate diagnosis."
Funding for the Chronic Migraine Epidemiology and Outcomes (CaMEO) study was provided by Allergan plc.
"Allergan is dedicated to advancing research to help the estimated 36 million Americans who are living with the debilitating effects of migraine,[iv]" said David Nicholson, Chief R&D Officer at Allergan. "The more information patients have, the better equipped they will be to make critical decisions about their own health, including when to seek help and what treatment options are available."
For more information about Chronic Migraine, including a screening tool, visit MyChronicMigraine.com.
About AllerganAllergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.
For more information, visit Allergan's website at www.allergan.com.
Forward-Looking StatementStatements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 (certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
For more information, visit Allergan's website at www.allergan.com.
iScher I. Ann, PhD, et al. Epidemiology of Migraine in Men: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.iiHeadache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 3rd edition. Cephalalgia. 2013;33(9):629–808.iiiKatsarava, Zaza, et al. "Defining the Differences Between Episodic Migraine and Chronic Migraine." Current Pain and Headache Reports. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3258393/ (Nov. 15, 2011).ivAmerican Migraine Foundation. "About Migraine." http://www.americanmigrainefoundation.org/about-migraine/ (May 16, 2016)
CONTACTS:
Media: Mark Marmur(973) 906-1526
Lisa Kim(714) 246-3843
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/study-reveals-gender-differences-in-migraine-treatment-300282890.html
SOURCE Allergan plc
